Prognostication of the High-Risk WM Patient

Efstathios Kastritis; Maria Gavriatopoulou; Marie‐Christine Kyrtsonis; Michael Michael; Evdoxia Hadjiharissi; Argiris Symeonidis; Eurydiki Michalis; Panagiotis Repoussis; Konstantinos Tsatalas; Anastasia Sioni; Zafiris Kartasis; Ekaterini Stefanoudaki; Michael Voulgarelis; Sosana Delimpasi; Dimitra Gika; Elissavet Vervesou; Κωνσταντίνος Κωνσταντόπουλος; Garyfalia Kokkini; Athanasios Zomas; Paraskevi Roussou; Nikolaos Anagnostopoulos; Theofanis Economopoulos; Evangelos Terpos; Konstantinos Zervas; Meletios A Dimopoulos

doi:10.3816/clml.2011.n.028

Letter2025

Who Is the True High-Bleeding-Risk Patient?

Hironori Hara, Tsai Tsung-Ying, Yoshinobu Onuma, Patrick W. Serruys

Article2019

PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

Alessandra Tedeschi, Meletios A Dimopoulos, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Beatrice Mahé, Charles Herbaux, Leonard T. Heffner, Constantine S. Tam, Marzia Varettoni, M. Lia Palomba, J. Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, J. Li, Erik Poulsen, B. Hauns, Christian Buske, V. Leblond

Chapter in a book1995

The “At Risk” Patient Population

Jean Louis Vincent

Article2019

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

Alessandra Tedeschi, Meletios A Dimopoulos, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Beatrice Mahé, Charles Herbaux, Leonard T. Heffner, Constantine S. Tam, Marzia Varettoni, M. Lia Palomba, J. Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, J. Li, Erik Poulsen, B. Hauns, Christian Buske, V. Leblond

Article2019

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.

Alessandra Tedeschi, Meletios A Dimopoulos, Judith Trotman, Ramón García‐Sánz, David MacDonald, Beatrice Mahé, Charles Herbaux, Leonard T. Heffner, Constantine S. Tam, Marzia Varettoni, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Erik Poulsen, Bernhard Hauns, Christian Buske, Véronique Leblond

Prognostication of the High-Risk WM Patient

Discussion(0)

Related publications

Who Is the True High-Bleeding-Risk Patient?

PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

The “At Risk” Patient Population

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.